Summary
Metodesnitazene, also recognized as Metazene, belongs to the class of benzimidazole derivatives, exhibiting opioid-like properties. However, in contrast to closely related substances like metonitazene and etodesnitazene, which display significantly higher potency, metodesnitazene demonstrates a level of power in animal studies that is roughly equivalent to morphine. In December 2021, the United States Drug Enforcement Administration (DEA) initiated discussions regarding the potential legal control and regulation of metodesnitazene.
| Identifiers | |
|---|---|
| IUPAC name | |
| CAS Number | 14030-77-4 1071546-40-1 (HCl) |
|---|---|
| PubChem CID | 26412 |
| CompTox Dashboard (EPA) | DTXSID80161305 |
| Chemical and physical data | |
| Formula | C21H27N3O |
| Molar mass | 337.467 g·mol−1 |
FAQ
1. What is Metodesnitazene?
- Metodesnitazene, also known as Metazene, is a benzimidazole derivative that exhibits opioid-like effects. It’s classified as a research chemical and is structurally related to other synthetic opioids.
2. How does Metodesnitazene work?
- Metodesnitazene acts on opioid receptors in the brain and nervous system, producing analgesic (pain relief) and potentially sedative effects. These effects are similar to those of natural opioids like morphine.
3. Is Metodesnitazene legal?
- The legal status of Metodesnitazene varies by country and region. In some places, it may be considered a controlled substance, while in others, it may be unregulated. Always check your local laws and regulations before obtaining or using this substance.
4. What are the potential risks associated with Metodesnitazene?
- The use of Metodesnitazene carries risks, including addiction, respiratory depression, overdose, and potential side effects such as nausea, constipation, and sedation. Its safety profile is not well-established, and it may be more dangerous than traditional opioids due to its potency.
5. Is Metodesnitazene for medical use?
- Metodesnitazene is not approved for medical use in most countries. It is primarily found in research and laboratory settings and is not prescribed by healthcare professionals.
6. Can I use Metodesnitazene recreationally?
- While some individuals may use Metodesnitazene for recreational purposes, it is not recommended due to the associated health risks. The substance’s potency and potential for addiction make it particularly dangerous when used recreationally.
7. How should Metodesnitazene be used if prescribed by a doctor?
- In general, Metodesnitazene is not prescribed by doctors for medical use. If you believe you require opioid-based medication for pain management, consult a healthcare professional who can provide safe and legal alternatives.
8. How can I reduce the risks associated with Metodesnitazene use?
- If you are using Metodesnitazene or considering doing so, it is essential to exercise caution. Minimize your risk by adhering to recommended dosages, avoiding simultaneous use of other substances (especially other opioids), and being aware of the signs of overdose.
9. What should I do if I or someone I know is experiencing an overdose of Metodesnitazene?
- In the event of a suspected overdose, seek immediate medical attention by calling emergency services. Administering naloxone, if available, can be life-saving in cases of opioid overdose.
10. Can I buy Metodesnitazene online?
- The availability of Metodesnitazene for purchase online may vary. However, buying substances online carries significant risks, including legality issues, uncertainty about the quality and purity of the product, and potential harm to your health.
References
- Hunger A, Kebrle J, Rossi A, Hoffmann K (1960). “Exploring Benzimidazole Derivatives and Related Heterocycles: Part II – The Synthesis of 1-Aminoalkyl-2-Benzyl-Benzimidazoles”. In the pages of Helvetica Chimica Acta, Volume 43, Issue 3, this research delves into the synthesis of 1-aminoalkyl-2-benzyl-benzimidazoles, shedding light on their chemical structure and properties. doi:10.1002/hlca.19600430323.
- Vandeputte M, Van Uytfanghe K, Layle N, Germaine DS, Iula D, Stove C (12 November 2020). “Unveiling Nitazene New Synthetic Opioids: Synthesis, Chemical Characterization, and Assessment of µ-Opioid Receptor Activity.” Authorea presents research on the synthesis and chemical characterization of a novel group of nitazene new synthetic opioids, investigating their potential activity on the µ-opioid receptor. doi:10.22541/au.160520665.59016513/v1. S2CID 234646245.
- Ujváry I, Christie R, Evans-Brown M, Gallegos A, Jorge R, de Morais J, Sedefov R (April 2021). “DARK Classics in Chemical Neuroscience: Etonitazene and the World of Benzimidazoles.” In ACS Chemical Neuroscience, Volume 12, Issue 7, this research discusses etonitazene and related benzimidazoles, shedding light on their significance in the realm of chemical neuroscience. doi:10.1021/acschemneuro.1c00037. PMID 33760580. S2CID 232356192.
- Lamy FR, Daniulaityte R, Barratt MJ, Lokala U, Sheth A, Carlson RG (August 2021). “Exploring Non-Fentanyl Novel Synthetic Opioids: The Case of ‘Etazene’.” In Drug and Alcohol Dependence, Volume 225, the study investigates non-fentanyl novel synthetic opioids, including ‘Etazene,’ and their presence on a darknet market. doi:10.1016/j.drugalcdep.2021.108790. PMID 34091156. S2CID 235362241.
- Sisco E, Burns A, Moorthy A (2021). “Development and Evaluation of a Synthetic Opioid Targeted Gas Chromatography Mass Spectrometry (GC-MS) Method.” This research, featured in the Journal of Forensic Sciences, Volume 66, Issue 6, presents the development and evaluation of a targeted GC-MS method for synthetic opioid analysis. doi:10.33774/chemrxiv-2021-0pcnq. PMC 9922096. PMID 34459514. S2CID 240520700.
- “Schedules of Controlled Substances: Temporary Placement of Butonitazene, Etodesnitazene, Flunitazene, Metodesnitazene, Metonitazene, N-pyrrolidino etonitazene, and Protonitazene in Schedule I.” This notice, issued by the Drug Enforcement Administration on 7 December 2021, discusses the proposed temporary placement of various substances in Schedule I of controlled substances, including Metodesnitazene, and highlights regulatory actions concerning these compounds.